Harmony Biosciences Holdings (HRMY) Short term Debt (2021 - 2026)

Harmony Biosciences Holdings' Short term Debt history runs 6 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• In Q1 2026, Short term Debt rose 14.29% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $20.0 million (up 14.29% YoY), while the FY2025 annual figure was $20.0 million, up 23.08% from the prior year.
• Short term Debt came in at $20.0 million for Q1 2026 at Harmony Biosciences Holdings, roughly flat from $20.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $20.0 million in Q3 2025 to a low of $2.0 million in Q1 2022.
• A 5-year average of $12.5 million and a median of $15.0 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt changed 0.0% in 2022 and surged 650.0% in 2023, its largest moves.
• Harmony Biosciences Holdings' Short term Debt stood at $2.0 million in 2022, then soared by 650.0% to $15.0 million in 2023, then advanced by 8.33% to $16.2 million in 2024, then gained by 23.08% to $20.0 million in 2025, then changed by 0.0% to $20.0 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $20.0 million, $20.0 million, and $20.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison